(Q38100847)

28 August 2017

Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B. (English)

1 reference

28 August 2017

1 reference

1

Eiji Tanaka

1 reference

28 August 2017

Akihiro Matsumoto

2

1 reference

28 August 2017

7 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

44

1 reference

28 August 2017

1

1 reference

28 August 2017

1-8

1 reference

Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.

28 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Experimental transmission of duck hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Chronic hepatitis B: back to the future with HBsAg

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12108

21 January 2018

Identifiers

DOI

10.1111/HEPR.12108

1 reference

28 August 2017

1 reference

PubMed ID

23607862